Macrocyclic compounds as inhibitors of KRAS mutants for cancer treatment

Abstract

The present invention relates to four macrocyclic compounds for use as KRAS mutant inhibitors for the treatment of cancer. As the compound 1-[4-(dimethylamino)-4-methyl-pent-2-inoyl]-N-[(1S)-1-[[(6S,8S,14S)-22-ethyl-25-fluoro- (21M)-21-[2-[(1S)-1-methoxyethyl]-3-pyridyl]-18,18-dimethyl-9,15-dioxo-5,16-dioxa-2,10,22,28-tetrazapentacyclo[18.5.2.1 2,6.1 10,14.0 23,27]nonacosa-1(26),20,23(27),24-tetraen-8-yl]carbamoyl]-2-methyl-propyl]-4-fluoro-N-methyl-piperidine-4-carboxamide, or a pharmaceutically acceptable salt thereof.